ArticlePharmaceutical research2012
Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 66 citations in OpenAlex.
- Association between the subsequent benign prostate hyperplasia-related surgery risk and patients treated with Chinese herbal medicine: a population-based Taiwanese cohort study.BMC complementary medicine and therapies · 2026Article
- Integrative analysis reveals PRKCB and SRD5A2 as potential immune-associated biomarkers in prostate cancer targeted by traditional Chinese medicine.Frontiers in oncology · 2026Article
- Tanshinone, a Natural NADPH Oxidase Inhibitor, Mitigates Testosterone-Induced Hair Loss.Biomolecules & therapeutics · 2025Article
- A review of tanshinone compounds in prostate cancer treatment.Translational andrology and urology · 2024Review
- Salvia miltiorrhiza bunge extracts: a promising source for anti-atopic dermatitis activity.BMC complementary medicine and therapies · 2024Article
- Photothermally enhanced antibacterial wound healing using albumin-loaded tanshinone IIA and IR780 nanoparticles.Frontiers in bioengineering and biotechnology · 2024Article
- PPARG is a potential target of Tanshinone IIA in prostate cancer treatment: a combination study of molecular docking and dynamic simulation based on transcriptomic bioinformatics.European journal of medical research · 2023Article
- Molecular Mechanism of Tanshinone against Prostate Cancer.Molecules (Basel, Switzerland) · 2022Review
- Potential role of astrocyte angiotensin converting enzyme 2 in the neural transmission of COVID-19 and a neuroinflammatory state induced by smoking and vaping.Fluids and barriers of the CNS · 2022Article
- The Influence of Selected Factors on the Aqueous Cryptotanshinone Solubility.Pharmaceutics · 2021Article
- Danshen (Frontiers in pharmacology · 2021Article
- An overview of the anti-cancer actions of Tanshinones, derived fromExploration of targeted anti-tumor therapy · 2020Review
- Tanshinone IIA: A Review of its Anticancer Effects.Frontiers in pharmacology · 2020Review
- Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.Cancer immunology, immunotherapy : CII · 2019Article
- Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.Molecular cancer therapeutics · 2018Article
- Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma.Oncotarget · 2017Article
- Acetonitrile extract ofOncology letters · 2017Article
- Article
- Quality Evaluation and Chemical Markers Screening of Salvia miltiorrhiza Bge. (Danshen) Based on HPLC Fingerprints and HPLC-MSMolecules (Basel, Switzerland) · 2017Article
- Danshen protects against early-stage alcoholic liver disease in mice via inducing PPARα activation and subsequent 4-HNE degradation.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
purposeTo test whether tanshinones inhibit prostate cancer (PCa) growth at least in part through inhibiting androgen receptor (AR) signaling.
methodsWe evaluated cell growth, survival and AR signaling parameters of PCa cells after exposure to tanshinones in in vitro models. We also tested the in vivo inhibitory efficacy of tanshinone IIA (TIIA) against LNCaP xenograft model in athymic nude mice.
resultsFor androgen-dependent LNCaP cells, a colony growth assay showed strong inhibitory potency following the order of TIIA≈cryptotanshinone>tanshinone I, being 10-30 folds higher than Casodex (racemic). TIIA inhibited growth of LNCaP cells more than several androgen-independent PCa cell lines. All 3 tested tanshinones were devoid of AR agonist activity under castrate condition. Mechanistically, tanshinones inhibited AR nuclear translocation within 2 h, decreased protein and mRNA abundance of AR and its target prostate-specific antigen within 12 h, and stimulated proteosomal degradation of AR. Oral administration of TIIA (25 mg/kg, once daily) retarded LNCaP xenograft growth and down-regulated tumor AR abundance in athymic nude mice.
conclusionAR targeting action of tanshinones was distinct from Casodex and contributed to prostate cancer growth suppression in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.